How Does Green Cross Company Actually Work?

Green Cross company's main product is Alyglo, an intravenous immunoglobulin (IVIG) for primary humoral immunodeficiency; Alyglo generated over 150 billion won (about 106 million USD) in the U.S. market in 2025. The portfolio also includes Hunterase for Hunter syndrome (74.4 billion won in 2025) and vaccines such as Barycela Injection for varicella (32.1 billion won in 2025) plus seasonal influenza doses.

Customers are immunodeficiency patients, rare – disease clinics, hospitals, government immunization programs, and distributors; Green Cross won a bid for 2.63 million seasonal flu vaccine doses for the 2025-2026 Korean season, supporting public – health supply chains.

Patients gain access to proven therapies for immune deficiencies and rare disorders; health systems get secure cold – chain logistics and regulatory – compliant vaccines, lowering hospitalization risk and outbreak exposure. Reliable plasma – derived supplies underpin predictable revenue streams and treatment continuity.

Clinicians and procurement agencies favor Green Cross for product efficacy, regulatory approvals, and manufacturing scale in plasma therapeutics; market share in key products like Alyglo and winning large public tenders makes it hard to replace. Read more on ownership and strategy in Who Owns Green Cross Company.

Plasma fractionation and specialty drugs are the primary revenue engines, with large government vaccine contracts adding steady volume; this mix delivers both margin and scale.

Revenue is segmented: plasma fractionation 560.2 billion won, prescription drugs 479.8 billion won, vaccines 300.6 billion won, and OTC/consumer health 119.7 billion won in 2025, diversifying cash flow and risk.

Most sales are reimbursed via national and private health insurers or paid directly through government vaccine tenders; price concessions and volume-based contracts shape realized prices.

U.S. product launches, notably Alyglo, are expanding margins while domestic Korean lines provide baseline stability; export growth increases pricing power and scale.

Green Cross is increasing its own plasma supply from roughly 14 percent of needs in 2024 toward a goal of 80 percent by 2028, which reduces third – party input costs and targets Alyglo operating margins above 30 percent by 2028.

Proprietary biologics like Alyglo, existing rare – disease pipeline candidates, established plasma collection sites, and GMP manufacturing capacity underpin Green Cross company operations and its route to higher margins and predictable supply.

The business depends heavily on success of Alyglo and a few rare – disease assets; valuation sensitivity is high-failure or delay in one lead candidate would materially reduce projected cash flows and revenue growth.

As of 2026 the company has entered a profit – improvement phase driven by integration and scale gains, but durability depends on pipeline diversification and sustaining plasma ramp versus global competitors with larger R&D budgets like Takeda and CSL Behring.